GoAI
Get started
Uni-Bio Science Group Limited logo

Uni-Bio Science Group Limited

0690.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$0.061

+HK$0.002 · +3.39%

Aug 21, 3:38 PM HKT

0690.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Uni-Bio Science Group Limited functions as an investment holding enterprise primarily engaged in the research, development, manufacturing, and distribution of biological and chemical pharmaceutical products aimed at treating human health conditions across the People's Republic of China. Its existing product range features GeneTime, a prescribed biological medication for promoting wound healing; GeneSoft, an EGF-based eye drop used to address dry eye syndrome, corneal damage, and to assist post-operative recovery; Pinup, a voriconazole tablet designed to combat severe fungal infections; and Bokangtai, a mitiglinide tablet prescribed for managing Type 2 diabetes, alongside Boshutai, an oral anti-diabetic drug tailored for patients with pre-diabetes. Additionally, the company is progressing with the development of several investigational prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; rhPTH 1-34 (Uni-PTH), targeting osteoporosis in postmenopausal women; and Uni-GLP, a GLP-1 agonist offering a non-insulin treatment alternative for Type 2 diabetes. The firm was established in 2001 and its headquarters are located in Sha Tin, Hong Kong.

Industry
Biotechnology
Sector
Healthcare
Headquarters
HK
CEO
Zhi Gang Zhao
Listed since
Nov 12, 2001
Employees
543

Market position

52-week range

Current HK$0.061

Open
HK$0.061
Previous close
HK$0.059
Volume
2.72M
0.86× average
Average volume
3.15M
Average daily volume
Market cap
364.24M HKD
Beta
-0.04
Market reference 1
50-day average
HK$0.0782
-21.97% below average
200-day average
HK$0.1002
-39.14% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
605.85M HKD
P/E (TTM)
3.91×
P/B (TTM)
0.89×
P/S (TTM)
0.62×
EV / EBITDA
5.59×
Earnings yield
13.57%
Free cash flow yield
5.54%
Dividend yield
5.13%

Profitability & efficiency

Gross margin
83.17%
Operating margin
0.00%
Net margin
15.92%
Return on equity
22.58%
Return on assets
16.10%
Return on invested capital
16.07%

Financial health

Debt / equity
0.24×
Current ratio
3.23×
Altman Z-score
0.69
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends92%57%21%-14%Gross margin, FY2021: 78.38%Gross margin, FY2022: 76.06%Gross margin, FY2023: 81.04%Gross margin, FY2024: 83.38%Gross margin, FY2025: 83.17%Operating margin, FY2021: -1.92%Operating margin, FY2022: 8.64%Operating margin, FY2023: 13.98%Operating margin, FY2024: 16.25%Operating margin, FY2025: 15.35%Net margin, FY2021: -5.54%Net margin, FY2022: 8.75%Net margin, FY2023: 14.62%Net margin, FY2024: 14.97%Net margin, FY2025: 15.92%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 78.38%. Gross margin FY2022 76.06%. Gross margin FY2023 81.04%. Gross margin FY2024 83.38%. Gross margin FY2025 83.17%. Operating margin FY2021 -1.92%. Operating margin FY2022 8.64%. Operating margin FY2023 13.98%. Operating margin FY2024 16.25%. Operating margin FY2025 15.35%. Net margin FY2021 -5.54%. Net margin FY2022 8.75%. Net margin FY2023 14.62%. Net margin FY2024 14.97%. Net margin FY2025 15.92%.

Income trends

Revenue

586.21M HKD+6.01%

Operating income

89.96M HKD+0.09%

Net income

93.33M HKD+12.75%
Income trends across reported periods646.79M HKD404.47M HKD162.15M HKD−80.17M HKDRevenue, FY2021: 353.41M HKDRevenue, FY2022: 440.32M HKDRevenue, FY2023: 484.72M HKDRevenue, FY2024: 552.98M HKDRevenue, FY2025: 586.21M HKDOperating income, FY2021: −6.79M HKDOperating income, FY2022: 38.05M HKDOperating income, FY2023: 67.77M HKDOperating income, FY2024: 89.87M HKDOperating income, FY2025: 89.96M HKDNet income, FY2021: −19.59M HKDNet income, FY2022: 38.51M HKDNet income, FY2023: 70.88M HKDNet income, FY2024: 82.77M HKDNet income, FY2025: 93.33M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 353.41M HKD. Revenue FY2022 440.32M HKD. Revenue FY2023 484.72M HKD. Revenue FY2024 552.98M HKD. Revenue FY2025 586.21M HKD. Operating income FY2021 −6.79M HKD. Operating income FY2022 38.05M HKD. Operating income FY2023 67.77M HKD. Operating income FY2024 89.87M HKD. Operating income FY2025 89.96M HKD. Net income FY2021 −19.59M HKD. Net income FY2022 38.51M HKD. Net income FY2023 70.88M HKD. Net income FY2024 82.77M HKD. Net income FY2025 93.33M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue586.21M HKD552.98M HKD484.72M HKD440.32M HKD353.41M HKD
Cost of goods sold98.65M HKD91.91M HKD91.9M HKD105.43M HKD76.4M HKD
Gross profit487.56M HKD461.07M HKD392.82M HKD334.88M HKD277.01M HKD
Research and development44.14M HKD56.66M HKD36.4M HKD35.78M HKD50.22M HKD
Selling, general, and administrative353.47M HKD312.42M HKD288.65M HKD258.31M HKD232.85M HKD
Operating expenses397.61M HKD371.2M HKD325.05M HKD292.63M HKD287.89M HKD
Interest income3.06M HKD3.35M HKD1.35M HKD1.3M HKD471K HKD
Interest expense1.51M HKD1.19M HKD783K HKD376K HKD477K HKD
Depreciation and amortization11.09M HKD21.35M HKD16.88M HKD17.55M HKD20.85M HKD
Operating income89.96M HKD89.87M HKD67.77M HKD38.05M HKD−6.79M HKD
Net income93.33M HKD82.77M HKD70.88M HKD38.51M HKD−19.59M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.050.02-0.01-0.04Q2 '21Q4 '21Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25
Q2 2021, reported Jun 30, 2021: actual 0, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual -0.003, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 29, 2022: actual 0.002, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 28, 2023: actual 0.004, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 28, 2023: actual 0.006, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 28, 2024: actual 0.005, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 28, 2024: actual 0.011, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 27, 2025: actual 0.003, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates290.54M242.3M194.05M145.81MQ2 '21Q4 '21Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25
Q2 2021, reported Jun 30, 2021: actual 156.98M HKD, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 196.42M HKD, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 29, 2022: actual 195.58M HKD, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 28, 2023: actual 244.74M HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 28, 2023: actual 249.93M HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 28, 2024: actual 234.79M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 28, 2024: actual 273.62M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 27, 2025: actual 279.37M HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.0028

2025 complete year+23.7% since 2007

2026 partial: HK$0.0031

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend May 28, 2026

HK$0.0031

Annual

Record May 29, 2026 · Payment Jun 12, 2026

Dividend

Ex-dividend May 28, 2025

HK$0.0028

Annual

Record May 29, 2025 · Payment Jun 13, 2025

Dividend

Ex-dividend Aug 22, 2007

HK$0.006

Special

0690.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

ETFs holding 0690.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Dimensional - Emerging Markets Core Equity 2 ETF logoDimensional - Emerging Markets Core Equity 2 ETFDFEM
Market value
5.42K
Weight
0.00%
AUM
9.49B USD
Expense ratio
0.39%
Price / 1D
$39.93+0.50%

Continue in GoAI

Research 0690.HK

research.disclaimer